Skip to main content

Retail prices of nine formulations under Drugs Prices Control Order, 2013 get fixed by NPPA

 

Clinical courses

 

Clinical courses

As per notification dated 13 February 2018, NPPA fix retail prices of 9 formulations under Drugs Prices Control Order, 2013.

These formulation are
a.   The ceiling price for one Clomiphene Tablet 50 mg & 100 mg are  Rs 7.56 and Rs 11.08 respectively.
b.  The ceiling price of Adenosine Injection (3mg/ml) is Rs 89.34 for 1 ml.
c.  The ceiling price of Povidone Iodine (solution 10%) is  Rs. 0.76 for 1 ml.
d. Methylprednisolone Injection (40mg/ml) ceiling price is Rs 48.97 for 1 ml.
e. The ceiling price of Sodium Valproate CR tablet 500 mg is 8.85 for 1 tablet.
f. The ceiling price of  Isosorbide 5 Mononitrate Tablet 20 mg is 2.98 for 1 tablet.
g. The ceiling price of  Lignocaine Topical form(2-5%) is 0.98 for 1 gm or 1 ml.

The manufacturers of above said scheduled formulations shall revise the prices of all such formulations downward not exceeding the ceiling price specified.

The manufacturers not complying with the ceiling price specified shall be liable to deposit the overcharged amount along with interest.

Every retailer and dealer are required to display price list as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email